Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report issued on Tuesday,Benzinga reports. D. Boral Capital currently has a $5.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

Hoth Therapeutics Trading Down 5.6 %

HOTH stock opened at $1.02 on Tuesday. The business’s 50-day moving average price is $1.13 and its two-hundred day moving average price is $0.94. The firm has a market cap of $7.04 million, a PE ratio of -0.77 and a beta of 0.80. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01). On average, analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent SEC filing. 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.